nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluticasone Propionate—PGR—ovarian cancer	0.446	1	CbGaD
Fluticasone Propionate—PLA2G4A—Epirubicin—ovarian cancer	0.192	0.542	CbGbCtD
Fluticasone Propionate—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0254	0.0716	CbGbCtD
Fluticasone Propionate—CYP3A7—Paclitaxel—ovarian cancer	0.0254	0.0716	CbGbCtD
Fluticasone Propionate—CYP3A5—Paclitaxel—ovarian cancer	0.019	0.0537	CbGbCtD
Fluticasone Propionate—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0183	0.0517	CbGbCtD
Fluticasone Propionate—CYP3A7—Docetaxel—ovarian cancer	0.0183	0.0517	CbGbCtD
Fluticasone Propionate—CYP3A4—Topotecan—ovarian cancer	0.015	0.0423	CbGbCtD
Fluticasone Propionate—CYP3A5—Docetaxel—ovarian cancer	0.0138	0.0388	CbGbCtD
Fluticasone Propionate—PGR—corpus luteum—ovarian cancer	0.0106	0.172	CbGeAlD
Fluticasone Propionate—CYP3A4—Vinorelbine—ovarian cancer	0.0106	0.0298	CbGbCtD
Fluticasone Propionate—PGR—ovarian follicle—ovarian cancer	0.00826	0.134	CbGeAlD
Fluticasone Propionate—CYP3A4—Paclitaxel—ovarian cancer	0.00742	0.0209	CbGbCtD
Fluticasone Propionate—CYP3A4—Docetaxel—ovarian cancer	0.00536	0.0151	CbGbCtD
Fluticasone Propionate—SERPINA6—oviduct—ovarian cancer	0.00478	0.0777	CbGeAlD
Fluticasone Propionate—CYP3A4—Doxorubicin—ovarian cancer	0.004	0.0113	CbGbCtD
Fluticasone Propionate—PGR—oviduct—ovarian cancer	0.00363	0.059	CbGeAlD
Fluticasone Propionate—PLA2G4A—myometrium—ovarian cancer	0.00154	0.025	CbGeAlD
Fluticasone Propionate—NR3C2—myometrium—ovarian cancer	0.00125	0.0203	CbGeAlD
Fluticasone Propionate—PLA2G4A—uterine cervix—ovarian cancer	0.0012	0.0194	CbGeAlD
Fluticasone Propionate—PGR—myometrium—ovarian cancer	0.00116	0.0189	CbGeAlD
Fluticasone Propionate—PLA2G4A—decidua—ovarian cancer	0.00114	0.0185	CbGeAlD
Fluticasone Propionate—PLA2G4A—endometrium—ovarian cancer	0.00108	0.0176	CbGeAlD
Fluticasone Propionate—NR3C2—uterine cervix—ovarian cancer	0.000972	0.0158	CbGeAlD
Fluticasone Propionate—PGR—epithelium—ovarian cancer	0.000911	0.0148	CbGeAlD
Fluticasone Propionate—PGR—uterine cervix—ovarian cancer	0.000904	0.0147	CbGeAlD
Fluticasone Propionate—PLA2G4A—female reproductive system—ovarian cancer	0.000896	0.0146	CbGeAlD
Fluticasone Propionate—SERPINA6—female reproductive system—ovarian cancer	0.000892	0.0145	CbGeAlD
Fluticasone Propionate—NR3C2—endometrium—ovarian cancer	0.000879	0.0143	CbGeAlD
Fluticasone Propionate—PGR—decidua—ovarian cancer	0.000861	0.014	CbGeAlD
Fluticasone Propionate—PLA2G4A—bone marrow—ovarian cancer	0.000846	0.0137	CbGeAlD
Fluticasone Propionate—SERPINA6—bone marrow—ovarian cancer	0.000842	0.0137	CbGeAlD
Fluticasone Propionate—PGR—endometrium—ovarian cancer	0.000817	0.0133	CbGeAlD
Fluticasone Propionate—PLA2G4A—female gonad—ovarian cancer	0.000815	0.0132	CbGeAlD
Fluticasone Propionate—NR3C2—uterus—ovarian cancer	0.00081	0.0132	CbGeAlD
Fluticasone Propionate—PLA2G4A—vagina—ovarian cancer	0.00081	0.0132	CbGeAlD
Fluticasone Propionate—PGR—uterus—ovarian cancer	0.000753	0.0122	CbGeAlD
Fluticasone Propionate—NR3C2—female reproductive system—ovarian cancer	0.000728	0.0118	CbGeAlD
Fluticasone Propionate—PLA2G4A—testis—ovarian cancer	0.000723	0.0118	CbGeAlD
Fluticasone Propionate—PGR—female reproductive system—ovarian cancer	0.000677	0.011	CbGeAlD
Fluticasone Propionate—NR3C1—myometrium—ovarian cancer	0.00067	0.0109	CbGeAlD
Fluticasone Propionate—NR3C2—female gonad—ovarian cancer	0.000663	0.0108	CbGeAlD
Fluticasone Propionate—NR3C2—vagina—ovarian cancer	0.000659	0.0107	CbGeAlD
Fluticasone Propionate—NR3C1—embryo—ovarian cancer	0.000644	0.0105	CbGeAlD
Fluticasone Propionate—PGR—female gonad—ovarian cancer	0.000616	0.01	CbGeAlD
Fluticasone Propionate—PGR—vagina—ovarian cancer	0.000612	0.00995	CbGeAlD
Fluticasone Propionate—NR3C2—testis—ovarian cancer	0.000588	0.00956	CbGeAlD
Fluticasone Propionate—PGR—testis—ovarian cancer	0.000546	0.00888	CbGeAlD
Fluticasone Propionate—NR3C1—epithelium—ovarian cancer	0.000526	0.00855	CbGeAlD
Fluticasone Propionate—CYP3A5—uterine cervix—ovarian cancer	0.000525	0.00854	CbGeAlD
Fluticasone Propionate—PLA2G4A—lymph node—ovarian cancer	0.000524	0.00852	CbGeAlD
Fluticasone Propionate—NR3C1—uterine cervix—ovarian cancer	0.000521	0.00848	CbGeAlD
Fluticasone Propionate—NR3C1—decidua—ovarian cancer	0.000497	0.00808	CbGeAlD
Fluticasone Propionate—NR3C1—endometrium—ovarian cancer	0.000472	0.00767	CbGeAlD
Fluticasone Propionate—NR3C1—gonad—ovarian cancer	0.000437	0.00711	CbGeAlD
Fluticasone Propionate—NR3C1—uterus—ovarian cancer	0.000435	0.00707	CbGeAlD
Fluticasone Propionate—NR3C2—lymph node—ovarian cancer	0.000426	0.00693	CbGeAlD
Fluticasone Propionate—PGR—lymph node—ovarian cancer	0.000396	0.00644	CbGeAlD
Fluticasone Propionate—NR3C1—female reproductive system—ovarian cancer	0.000391	0.00635	CbGeAlD
Fluticasone Propionate—NR3C1—bone marrow—ovarian cancer	0.000369	0.006	CbGeAlD
Fluticasone Propionate—CYP3A5—female gonad—ovarian cancer	0.000358	0.00582	CbGeAlD
Fluticasone Propionate—CYP3A5—vagina—ovarian cancer	0.000356	0.00579	CbGeAlD
Fluticasone Propionate—NR3C1—female gonad—ovarian cancer	0.000355	0.00578	CbGeAlD
Fluticasone Propionate—NR3C1—vagina—ovarian cancer	0.000353	0.00574	CbGeAlD
Fluticasone Propionate—NR3C1—testis—ovarian cancer	0.000315	0.00513	CbGeAlD
Fluticasone Propionate—Betamethasone—PGR—ovarian cancer	0.000306	0.292	CrCbGaD
Fluticasone Propionate—CYP3A4—female reproductive system—ovarian cancer	0.000295	0.0048	CbGeAlD
Fluticasone Propionate—NR3C1—lymph node—ovarian cancer	0.000229	0.00372	CbGeAlD
Fluticasone Propionate—Dexamethasone—PGR—ovarian cancer	0.000178	0.17	CrCbGaD
Fluticasone Propionate—Dexamethasone—CYP1B1—ovarian cancer	0.000166	0.159	CrCbGaD
Fluticasone Propionate—Eczema—Epirubicin—ovarian cancer	0.000159	0.00167	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Docetaxel—ovarian cancer	0.000158	0.00166	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Topotecan—ovarian cancer	0.000157	0.00165	CcSEcCtD
Fluticasone Propionate—Pain—Vinorelbine—ovarian cancer	0.000156	0.00164	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Paclitaxel—ovarian cancer	0.000156	0.00164	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Paclitaxel—ovarian cancer	0.000155	0.00163	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Paclitaxel—ovarian cancer	0.000154	0.00162	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Melphalan—ovarian cancer	0.000154	0.00161	CcSEcCtD
Fluticasone Propionate—Epistaxis—Docetaxel—ovarian cancer	0.000154	0.00161	CcSEcCtD
Fluticasone Propionate—Vomiting—Chlorambucil—ovarian cancer	0.000152	0.0016	CcSEcCtD
Fluticasone Propionate—Diabetes mellitus—Doxorubicin—ovarian cancer	0.000152	0.00159	CcSEcCtD
Fluticasone Propionate—Mental disorder—Paclitaxel—ovarian cancer	0.000151	0.00159	CcSEcCtD
Fluticasone Propionate—Pruritus—Topotecan—ovarian cancer	0.000151	0.00158	CcSEcCtD
Fluticasone Propionate—Malnutrition—Paclitaxel—ovarian cancer	0.00015	0.00158	CcSEcCtD
Fluticasone Propionate—Erythema—Paclitaxel—ovarian cancer	0.00015	0.00158	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Vinorelbine—ovarian cancer	0.00015	0.00158	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Epirubicin—ovarian cancer	0.000149	0.00157	CcSEcCtD
Fluticasone Propionate—Fluticasone furoate—ABCB1—ovarian cancer	0.000149	0.142	CrCbGaD
Fluticasone Propionate—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000149	0.00156	CcSEcCtD
Fluticasone Propionate—Pruritus—Melphalan—ovarian cancer	0.000147	0.00155	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.000147	0.00155	CcSEcCtD
Fluticasone Propionate—Eczema—Doxorubicin—ovarian cancer	0.000147	0.00154	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Topotecan—ovarian cancer	0.000146	0.00153	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Docetaxel—ovarian cancer	0.000145	0.00153	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Docetaxel—ovarian cancer	0.000145	0.00152	CcSEcCtD
Fluticasone Propionate—Urticaria—Vinorelbine—ovarian cancer	0.000145	0.00152	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Paclitaxel—ovarian cancer	0.000144	0.00152	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Vinorelbine—ovarian cancer	0.000144	0.00151	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Vinorelbine—ovarian cancer	0.000144	0.00151	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Docetaxel—ovarian cancer	0.000144	0.00151	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Melphalan—ovarian cancer	0.000143	0.0015	CcSEcCtD
Fluticasone Propionate—Nausea—Chlorambucil—ovarian cancer	0.000142	0.00149	CcSEcCtD
Fluticasone Propionate—Vision blurred—Paclitaxel—ovarian cancer	0.000141	0.00149	CcSEcCtD
Fluticasone Propionate—Dizziness—Topotecan—ovarian cancer	0.000141	0.00148	CcSEcCtD
Fluticasone Propionate—Tremor—Paclitaxel—ovarian cancer	0.000141	0.00148	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000139	0.00146	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Doxorubicin—ovarian cancer	0.000138	0.00145	CcSEcCtD
Fluticasone Propionate—Agitation—Paclitaxel—ovarian cancer	0.000138	0.00145	CcSEcCtD
Fluticasone Propionate—Face oedema—Epirubicin—ovarian cancer	0.000138	0.00145	CcSEcCtD
Fluticasone Propionate—Angioedema—Paclitaxel—ovarian cancer	0.000137	0.00144	CcSEcCtD
Fluticasone Propionate—Eye disorder—Docetaxel—ovarian cancer	0.000137	0.00143	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.000136	0.00143	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Docetaxel—ovarian cancer	0.000136	0.00142	CcSEcCtD
Fluticasone Propionate—Vomiting—Topotecan—ovarian cancer	0.000135	0.00142	CcSEcCtD
Fluticasone Propionate—Malaise—Paclitaxel—ovarian cancer	0.000135	0.00142	CcSEcCtD
Fluticasone Propionate—Rash—Topotecan—ovarian cancer	0.000134	0.00141	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Vinorelbine—ovarian cancer	0.000134	0.00141	CcSEcCtD
Fluticasone Propionate—Dermatitis—Topotecan—ovarian cancer	0.000134	0.00141	CcSEcCtD
Fluticasone Propionate—Headache—Topotecan—ovarian cancer	0.000133	0.0014	CcSEcCtD
Fluticasone Propionate—Palpitations—Paclitaxel—ovarian cancer	0.000133	0.00139	CcSEcCtD
Fluticasone Propionate—Vomiting—Melphalan—ovarian cancer	0.000133	0.00139	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Docetaxel—ovarian cancer	0.000132	0.00139	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Docetaxel—ovarian cancer	0.000132	0.00138	CcSEcCtD
Fluticasone Propionate—Rash—Melphalan—ovarian cancer	0.000131	0.00138	CcSEcCtD
Fluticasone Propionate—Dermatitis—Melphalan—ovarian cancer	0.000131	0.00138	CcSEcCtD
Fluticasone Propionate—Cough—Paclitaxel—ovarian cancer	0.000131	0.00138	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Docetaxel—ovarian cancer	0.000131	0.00137	CcSEcCtD
Fluticasone Propionate—Hypertension—Paclitaxel—ovarian cancer	0.00013	0.00136	CcSEcCtD
Fluticasone Propionate—Pruritus—Vinorelbine—ovarian cancer	0.000129	0.00135	CcSEcCtD
Fluticasone Propionate—Mental disorder—Docetaxel—ovarian cancer	0.000128	0.00135	CcSEcCtD
Fluticasone Propionate—Chest pain—Paclitaxel—ovarian cancer	0.000128	0.00134	CcSEcCtD
Fluticasone Propionate—Arthralgia—Paclitaxel—ovarian cancer	0.000128	0.00134	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Epirubicin—ovarian cancer	0.000127	0.00134	CcSEcCtD
Fluticasone Propionate—Anxiety—Paclitaxel—ovarian cancer	0.000127	0.00134	CcSEcCtD
Fluticasone Propionate—Face oedema—Doxorubicin—ovarian cancer	0.000127	0.00134	CcSEcCtD
Fluticasone Propionate—Erythema—Docetaxel—ovarian cancer	0.000127	0.00134	CcSEcCtD
Fluticasone Propionate—Malnutrition—Docetaxel—ovarian cancer	0.000127	0.00134	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000127	0.00133	CcSEcCtD
Fluticasone Propionate—Nausea—Topotecan—ovarian cancer	0.000126	0.00133	CcSEcCtD
Fluticasone Propionate—Discomfort—Paclitaxel—ovarian cancer	0.000126	0.00133	CcSEcCtD
Fluticasone Propionate—Dry mouth—Paclitaxel—ovarian cancer	0.000125	0.00131	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Vinorelbine—ovarian cancer	0.000125	0.00131	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Epirubicin—ovarian cancer	0.000124	0.0013	CcSEcCtD
Fluticasone Propionate—Nausea—Melphalan—ovarian cancer	0.000124	0.0013	CcSEcCtD
Fluticasone Propionate—Asthma—Epirubicin—ovarian cancer	0.000123	0.00129	CcSEcCtD
Fluticasone Propionate—Oedema—Paclitaxel—ovarian cancer	0.000123	0.00129	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000123	0.00129	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Docetaxel—ovarian cancer	0.000122	0.00128	CcSEcCtD
Fluticasone Propionate—Infection—Paclitaxel—ovarian cancer	0.000122	0.00128	CcSEcCtD
Fluticasone Propionate—Dizziness—Vinorelbine—ovarian cancer	0.00012	0.00127	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Paclitaxel—ovarian cancer	0.00012	0.00126	CcSEcCtD
Fluticasone Propionate—Tachycardia—Paclitaxel—ovarian cancer	0.00012	0.00126	CcSEcCtD
Fluticasone Propionate—Skin disorder—Paclitaxel—ovarian cancer	0.000119	0.00125	CcSEcCtD
Fluticasone Propionate—Methylprednisolone—ABCB1—ovarian cancer	0.000119	0.113	CrCbGaD
Fluticasone Propionate—Bronchitis—Epirubicin—ovarian cancer	0.000118	0.00124	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Doxorubicin—ovarian cancer	0.000118	0.00124	CcSEcCtD
Fluticasone Propionate—Vomiting—Vinorelbine—ovarian cancer	0.000116	0.00122	CcSEcCtD
Fluticasone Propionate—Rash—Vinorelbine—ovarian cancer	0.000115	0.00121	CcSEcCtD
Fluticasone Propionate—Dermatitis—Vinorelbine—ovarian cancer	0.000115	0.00121	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Doxorubicin—ovarian cancer	0.000115	0.00121	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000114	0.0012	CcSEcCtD
Fluticasone Propionate—Headache—Vinorelbine—ovarian cancer	0.000114	0.0012	CcSEcCtD
Fluticasone Propionate—Asthma—Doxorubicin—ovarian cancer	0.000114	0.0012	CcSEcCtD
Fluticasone Propionate—Palpitations—Docetaxel—ovarian cancer	0.000112	0.00118	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000112	0.00117	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Epirubicin—ovarian cancer	0.000111	0.00117	CcSEcCtD
Fluticasone Propionate—Cough—Docetaxel—ovarian cancer	0.000111	0.00117	CcSEcCtD
Fluticasone Propionate—Pneumonia—Epirubicin—ovarian cancer	0.00011	0.00116	CcSEcCtD
Fluticasone Propionate—Hypertension—Docetaxel—ovarian cancer	0.00011	0.00115	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Epirubicin—ovarian cancer	0.00011	0.00115	CcSEcCtD
Fluticasone Propionate—Infestation—Epirubicin—ovarian cancer	0.00011	0.00115	CcSEcCtD
Fluticasone Propionate—Bronchitis—Doxorubicin—ovarian cancer	0.00011	0.00115	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Paclitaxel—ovarian cancer	0.000109	0.00115	CcSEcCtD
Fluticasone Propionate—Arthralgia—Docetaxel—ovarian cancer	0.000108	0.00114	CcSEcCtD
Fluticasone Propionate—Chest pain—Docetaxel—ovarian cancer	0.000108	0.00114	CcSEcCtD
Fluticasone Propionate—Nausea—Vinorelbine—ovarian cancer	0.000108	0.00114	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000108	0.00113	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Epirubicin—ovarian cancer	0.000107	0.00112	CcSEcCtD
Fluticasone Propionate—Dry mouth—Docetaxel—ovarian cancer	0.000106	0.00111	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000106	0.00111	CcSEcCtD
Fluticasone Propionate—Pain—Paclitaxel—ovarian cancer	0.000105	0.0011	CcSEcCtD
Fluticasone Propionate—Oedema—Docetaxel—ovarian cancer	0.000104	0.00109	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Docetaxel—ovarian cancer	0.000104	0.00109	CcSEcCtD
Fluticasone Propionate—Epistaxis—Epirubicin—ovarian cancer	0.000104	0.00109	CcSEcCtD
Fluticasone Propionate—Infection—Docetaxel—ovarian cancer	0.000103	0.00108	CcSEcCtD
Fluticasone Propionate—Sinusitis—Epirubicin—ovarian cancer	0.000103	0.00108	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000103	0.00108	CcSEcCtD
Fluticasone Propionate—Pneumonia—Doxorubicin—ovarian cancer	0.000102	0.00107	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Docetaxel—ovarian cancer	0.000102	0.00107	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Doxorubicin—ovarian cancer	0.000102	0.00107	CcSEcCtD
Fluticasone Propionate—Infestation—Doxorubicin—ovarian cancer	0.000102	0.00107	CcSEcCtD
Fluticasone Propionate—Tachycardia—Docetaxel—ovarian cancer	0.000101	0.00106	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Paclitaxel—ovarian cancer	0.000101	0.00106	CcSEcCtD
Fluticasone Propionate—Skin disorder—Docetaxel—ovarian cancer	0.000101	0.00106	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.0001	0.00105	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Doxorubicin—ovarian cancer	9.88e-05	0.00104	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Epirubicin—ovarian cancer	9.81e-05	0.00103	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Epirubicin—ovarian cancer	9.78e-05	0.00103	CcSEcCtD
Fluticasone Propionate—Urticaria—Paclitaxel—ovarian cancer	9.73e-05	0.00102	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Epirubicin—ovarian cancer	9.69e-05	0.00102	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Paclitaxel—ovarian cancer	9.68e-05	0.00102	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Paclitaxel—ovarian cancer	9.68e-05	0.00102	CcSEcCtD
Fluticasone Propionate—Epistaxis—Doxorubicin—ovarian cancer	9.58e-05	0.00101	CcSEcCtD
Fluticasone Propionate—Sinusitis—Doxorubicin—ovarian cancer	9.53e-05	0.001	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Docetaxel—ovarian cancer	9.46e-05	0.000994	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Docetaxel—ovarian cancer	9.26e-05	0.000972	CcSEcCtD
Fluticasone Propionate—Eye disorder—Epirubicin—ovarian cancer	9.21e-05	0.000968	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Epirubicin—ovarian cancer	9.15e-05	0.000961	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Doxorubicin—ovarian cancer	9.08e-05	0.000953	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Doxorubicin—ovarian cancer	9.05e-05	0.000951	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Paclitaxel—ovarian cancer	9.03e-05	0.000948	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Doxorubicin—ovarian cancer	8.96e-05	0.000942	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Epirubicin—ovarian cancer	8.9e-05	0.000935	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Epirubicin—ovarian cancer	8.88e-05	0.000933	CcSEcCtD
Fluticasone Propionate—Pain—Docetaxel—ovarian cancer	8.88e-05	0.000933	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Epirubicin—ovarian cancer	8.81e-05	0.000925	CcSEcCtD
Fluticasone Propionate—Pruritus—Paclitaxel—ovarian cancer	8.67e-05	0.00091	CcSEcCtD
Fluticasone Propionate—Mental disorder—Epirubicin—ovarian cancer	8.64e-05	0.000907	CcSEcCtD
Fluticasone Propionate—Malnutrition—Epirubicin—ovarian cancer	8.58e-05	0.000901	CcSEcCtD
Fluticasone Propionate—Erythema—Epirubicin—ovarian cancer	8.58e-05	0.000901	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Docetaxel—ovarian cancer	8.56e-05	0.000899	CcSEcCtD
Fluticasone Propionate—Eye disorder—Doxorubicin—ovarian cancer	8.52e-05	0.000895	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Docetaxel—ovarian cancer	8.49e-05	0.000892	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Doxorubicin—ovarian cancer	8.47e-05	0.000889	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Paclitaxel—ovarian cancer	8.38e-05	0.00088	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Epirubicin—ovarian cancer	8.25e-05	0.000867	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Doxorubicin—ovarian cancer	8.24e-05	0.000865	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Doxorubicin—ovarian cancer	8.22e-05	0.000864	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Docetaxel—ovarian cancer	8.21e-05	0.000862	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Docetaxel—ovarian cancer	8.21e-05	0.000862	CcSEcCtD
Fluticasone Propionate—Betamethasone—ABCB1—ovarian cancer	8.21e-05	0.0783	CrCbGaD
Fluticasone Propionate—Arrhythmia—Doxorubicin—ovarian cancer	8.15e-05	0.000856	CcSEcCtD
Fluticasone Propionate—Dizziness—Paclitaxel—ovarian cancer	8.1e-05	0.000851	CcSEcCtD
Fluticasone Propionate—Vision blurred—Epirubicin—ovarian cancer	8.09e-05	0.00085	CcSEcCtD
Fluticasone Propionate—Mental disorder—Doxorubicin—ovarian cancer	7.99e-05	0.000839	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Epirubicin—ovarian cancer	7.96e-05	0.000836	CcSEcCtD
Fluticasone Propionate—Malnutrition—Doxorubicin—ovarian cancer	7.94e-05	0.000834	CcSEcCtD
Fluticasone Propionate—Erythema—Doxorubicin—ovarian cancer	7.94e-05	0.000834	CcSEcCtD
Fluticasone Propionate—Agitation—Epirubicin—ovarian cancer	7.89e-05	0.000828	CcSEcCtD
Fluticasone Propionate—Vomiting—Paclitaxel—ovarian cancer	7.79e-05	0.000818	CcSEcCtD
Fluticasone Propionate—Malaise—Epirubicin—ovarian cancer	7.74e-05	0.000813	CcSEcCtD
Fluticasone Propionate—Rash—Paclitaxel—ovarian cancer	7.72e-05	0.000811	CcSEcCtD
Fluticasone Propionate—Dermatitis—Paclitaxel—ovarian cancer	7.72e-05	0.000811	CcSEcCtD
Fluticasone Propionate—Headache—Paclitaxel—ovarian cancer	7.67e-05	0.000806	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Docetaxel—ovarian cancer	7.65e-05	0.000804	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Doxorubicin—ovarian cancer	7.63e-05	0.000802	CcSEcCtD
Fluticasone Propionate—Palpitations—Epirubicin—ovarian cancer	7.58e-05	0.000797	CcSEcCtD
Fluticasone Propionate—Cough—Epirubicin—ovarian cancer	7.49e-05	0.000787	CcSEcCtD
Fluticasone Propionate—Vision blurred—Doxorubicin—ovarian cancer	7.48e-05	0.000786	CcSEcCtD
Fluticasone Propionate—Hypertension—Epirubicin—ovarian cancer	7.41e-05	0.000778	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Doxorubicin—ovarian cancer	7.37e-05	0.000774	CcSEcCtD
Fluticasone Propionate—Pruritus—Docetaxel—ovarian cancer	7.35e-05	0.000772	CcSEcCtD
Fluticasone Propionate—Chest pain—Epirubicin—ovarian cancer	7.31e-05	0.000767	CcSEcCtD
Fluticasone Propionate—Arthralgia—Epirubicin—ovarian cancer	7.31e-05	0.000767	CcSEcCtD
Fluticasone Propionate—Agitation—Doxorubicin—ovarian cancer	7.3e-05	0.000767	CcSEcCtD
Fluticasone Propionate—Anxiety—Epirubicin—ovarian cancer	7.28e-05	0.000765	CcSEcCtD
Fluticasone Propionate—Nausea—Paclitaxel—ovarian cancer	7.28e-05	0.000764	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	7.26e-05	0.000762	CcSEcCtD
Fluticasone Propionate—Discomfort—Epirubicin—ovarian cancer	7.22e-05	0.000758	CcSEcCtD
Fluticasone Propionate—Malaise—Doxorubicin—ovarian cancer	7.16e-05	0.000752	CcSEcCtD
Fluticasone Propionate—Dry mouth—Epirubicin—ovarian cancer	7.15e-05	0.000751	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Docetaxel—ovarian cancer	7.1e-05	0.000746	CcSEcCtD
Fluticasone Propionate—Palpitations—Doxorubicin—ovarian cancer	7.02e-05	0.000737	CcSEcCtD
Fluticasone Propionate—Oedema—Epirubicin—ovarian cancer	7e-05	0.000736	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Epirubicin—ovarian cancer	7e-05	0.000736	CcSEcCtD
Fluticasone Propionate—Infection—Epirubicin—ovarian cancer	6.96e-05	0.000731	CcSEcCtD
Fluticasone Propionate—Cough—Doxorubicin—ovarian cancer	6.93e-05	0.000728	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Epirubicin—ovarian cancer	6.87e-05	0.000721	CcSEcCtD
Fluticasone Propionate—Dizziness—Docetaxel—ovarian cancer	6.87e-05	0.000721	CcSEcCtD
Fluticasone Propionate—Hypertension—Doxorubicin—ovarian cancer	6.86e-05	0.00072	CcSEcCtD
Fluticasone Propionate—Tachycardia—Epirubicin—ovarian cancer	6.84e-05	0.000718	CcSEcCtD
Fluticasone Propionate—Skin disorder—Epirubicin—ovarian cancer	6.8e-05	0.000715	CcSEcCtD
Fluticasone Propionate—Arthralgia—Doxorubicin—ovarian cancer	6.76e-05	0.00071	CcSEcCtD
Fluticasone Propionate—Chest pain—Doxorubicin—ovarian cancer	6.76e-05	0.00071	CcSEcCtD
Fluticasone Propionate—Anxiety—Doxorubicin—ovarian cancer	6.74e-05	0.000708	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	6.71e-05	0.000705	CcSEcCtD
Fluticasone Propionate—Discomfort—Doxorubicin—ovarian cancer	6.68e-05	0.000702	CcSEcCtD
Fluticasone Propionate—Dry mouth—Doxorubicin—ovarian cancer	6.61e-05	0.000694	CcSEcCtD
Fluticasone Propionate—Vomiting—Docetaxel—ovarian cancer	6.6e-05	0.000694	CcSEcCtD
Fluticasone Propionate—Rash—Docetaxel—ovarian cancer	6.55e-05	0.000688	CcSEcCtD
Fluticasone Propionate—Dermatitis—Docetaxel—ovarian cancer	6.54e-05	0.000687	CcSEcCtD
Fluticasone Propionate—Headache—Docetaxel—ovarian cancer	6.5e-05	0.000683	CcSEcCtD
Fluticasone Propionate—Oedema—Doxorubicin—ovarian cancer	6.48e-05	0.000681	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Doxorubicin—ovarian cancer	6.48e-05	0.000681	CcSEcCtD
Fluticasone Propionate—Infection—Doxorubicin—ovarian cancer	6.44e-05	0.000676	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Epirubicin—ovarian cancer	6.38e-05	0.00067	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Doxorubicin—ovarian cancer	6.36e-05	0.000668	CcSEcCtD
Fluticasone Propionate—Tachycardia—Doxorubicin—ovarian cancer	6.32e-05	0.000664	CcSEcCtD
Fluticasone Propionate—Skin disorder—Doxorubicin—ovarian cancer	6.29e-05	0.000661	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Epirubicin—ovarian cancer	6.24e-05	0.000656	CcSEcCtD
Fluticasone Propionate—Nausea—Docetaxel—ovarian cancer	6.17e-05	0.000648	CcSEcCtD
Fluticasone Propionate—Pain—Epirubicin—ovarian cancer	5.99e-05	0.000629	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	5.9e-05	0.00062	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Doxorubicin—ovarian cancer	5.78e-05	0.000607	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Epirubicin—ovarian cancer	5.77e-05	0.000606	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Epirubicin—ovarian cancer	5.73e-05	0.000602	CcSEcCtD
Fluticasone Propionate—Urticaria—Epirubicin—ovarian cancer	5.56e-05	0.000584	CcSEcCtD
Fluticasone Propionate—Pain—Doxorubicin—ovarian cancer	5.54e-05	0.000582	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Epirubicin—ovarian cancer	5.54e-05	0.000582	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Epirubicin—ovarian cancer	5.54e-05	0.000582	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Doxorubicin—ovarian cancer	5.34e-05	0.000561	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Doxorubicin—ovarian cancer	5.3e-05	0.000557	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Epirubicin—ovarian cancer	5.16e-05	0.000542	CcSEcCtD
Fluticasone Propionate—Urticaria—Doxorubicin—ovarian cancer	5.15e-05	0.000541	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Doxorubicin—ovarian cancer	5.12e-05	0.000538	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Doxorubicin—ovarian cancer	5.12e-05	0.000538	CcSEcCtD
Fluticasone Propionate—Pruritus—Epirubicin—ovarian cancer	4.96e-05	0.000521	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Epirubicin—ovarian cancer	4.79e-05	0.000503	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Doxorubicin—ovarian cancer	4.77e-05	0.000502	CcSEcCtD
Fluticasone Propionate—Dexamethasone—ABCB1—ovarian cancer	4.77e-05	0.0456	CrCbGaD
Fluticasone Propionate—Dizziness—Epirubicin—ovarian cancer	4.63e-05	0.000487	CcSEcCtD
Fluticasone Propionate—Pruritus—Doxorubicin—ovarian cancer	4.58e-05	0.000482	CcSEcCtD
Fluticasone Propionate—Vomiting—Epirubicin—ovarian cancer	4.45e-05	0.000468	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Doxorubicin—ovarian cancer	4.43e-05	0.000466	CcSEcCtD
Fluticasone Propionate—Rash—Epirubicin—ovarian cancer	4.42e-05	0.000464	CcSEcCtD
Fluticasone Propionate—Dermatitis—Epirubicin—ovarian cancer	4.41e-05	0.000463	CcSEcCtD
Fluticasone Propionate—Headache—Epirubicin—ovarian cancer	4.39e-05	0.000461	CcSEcCtD
Fluticasone Propionate—Dizziness—Doxorubicin—ovarian cancer	4.29e-05	0.00045	CcSEcCtD
Fluticasone Propionate—Nausea—Epirubicin—ovarian cancer	4.16e-05	0.000437	CcSEcCtD
Fluticasone Propionate—Vomiting—Doxorubicin—ovarian cancer	4.12e-05	0.000433	CcSEcCtD
Fluticasone Propionate—Rash—Doxorubicin—ovarian cancer	4.09e-05	0.000429	CcSEcCtD
Fluticasone Propionate—Dermatitis—Doxorubicin—ovarian cancer	4.08e-05	0.000429	CcSEcCtD
Fluticasone Propionate—Headache—Doxorubicin—ovarian cancer	4.06e-05	0.000426	CcSEcCtD
Fluticasone Propionate—Nausea—Doxorubicin—ovarian cancer	3.85e-05	0.000404	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—ovarian cancer	3.83e-05	0.000912	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—PIK3CA—ovarian cancer	3.79e-05	0.000903	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—CTNNB1—ovarian cancer	3.78e-05	0.000901	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—IL6—ovarian cancer	3.78e-05	0.0009	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—PARP1—ovarian cancer	3.75e-05	0.000892	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PPP1CC—ovarian cancer	3.73e-05	0.000887	CbGpPWpGaD
Fluticasone Propionate—PGR—Generic Transcription Pathway—ESR1—ovarian cancer	3.72e-05	0.000886	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—HRAS—ovarian cancer	3.67e-05	0.000875	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—BRIP1—ovarian cancer	3.64e-05	0.000867	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PPP1CC—ovarian cancer	3.64e-05	0.000867	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—TP53—ovarian cancer	3.64e-05	0.000866	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—IL2—ovarian cancer	3.62e-05	0.000863	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	3.54e-05	0.000844	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—IL6—ovarian cancer	3.52e-05	0.000837	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—HRAS—ovarian cancer	3.51e-05	0.000836	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Phospholipid metabolism—PIK3CA—ovarian cancer	3.51e-05	0.000835	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—VEGFA—ovarian cancer	3.46e-05	0.000824	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	3.39e-05	0.000808	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—IL6—ovarian cancer	3.33e-05	0.000793	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—STAT3—ovarian cancer	3.3e-05	0.000785	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK3—ovarian cancer	3.27e-05	0.000779	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	3.27e-05	0.000779	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—NME2—ovarian cancer	3.26e-05	0.000775	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—AKT1—ovarian cancer	3.24e-05	0.000772	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—DOK1—ovarian cancer	3.24e-05	0.000771	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—ovarian cancer	3.18e-05	0.000758	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Generic Transcription Pathway—MYC—ovarian cancer	3.18e-05	0.000757	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—PARP1—ovarian cancer	3.12e-05	0.000743	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—MAPK1—ovarian cancer	3.11e-05	0.000742	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—ovarian cancer	3.11e-05	0.000741	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—ovarian cancer	3.1e-05	0.000739	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—VEGFA—ovarian cancer	3.08e-05	0.000733	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—AKT1—ovarian cancer	3.07e-05	0.000732	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PPP1CC—ovarian cancer	3.04e-05	0.000725	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—ESR1—ovarian cancer	2.94e-05	0.0007	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—ovarian cancer	2.94e-05	0.0007	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—CAV1—ovarian cancer	2.91e-05	0.000694	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—MAPK3—ovarian cancer	2.91e-05	0.000693	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—CYTB—ovarian cancer	2.9e-05	0.000691	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	2.88e-05	0.000685	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—HDAC6—ovarian cancer	2.82e-05	0.000672	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—MAPK1—ovarian cancer	2.77e-05	0.00066	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	2.7e-05	0.000643	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—PIK3CG—ovarian cancer	2.65e-05	0.000632	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	2.65e-05	0.000631	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	2.61e-05	0.000622	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—BRIP1—ovarian cancer	2.54e-05	0.000604	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PPP1CC—ovarian cancer	2.54e-05	0.000604	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—PPP2R1A—ovarian cancer	2.53e-05	0.000603	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—YAP1—ovarian cancer	2.5e-05	0.000595	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.48e-05	0.000591	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.45e-05	0.000583	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—XIAP—ovarian cancer	2.45e-05	0.000583	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—YAP1—ovarian cancer	2.44e-05	0.000581	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	2.42e-05	0.000575	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—PIK3CA—ovarian cancer	2.4e-05	0.000573	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—SMARCA4—ovarian cancer	2.39e-05	0.000568	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—PIK3CD—ovarian cancer	2.33e-05	0.000555	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—EREG—ovarian cancer	2.33e-05	0.000554	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—HDAC6—ovarian cancer	2.31e-05	0.000549	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—IL6—ovarian cancer	2.3e-05	0.000548	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PPP2R1A—ovarian cancer	2.28e-05	0.000542	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—YAP1—ovarian cancer	2.22e-05	0.000529	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	2.21e-05	0.000526	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—ESR1—ovarian cancer	2.15e-05	0.000512	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	2.12e-05	0.000506	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—CYTB—ovarian cancer	2.1e-05	0.000499	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—YAP1—ovarian cancer	2.04e-05	0.000486	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—PIK3CB—ovarian cancer	2.03e-05	0.000484	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PARP1—ovarian cancer	2.03e-05	0.000483	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—XIAP—ovarian cancer	2e-05	0.000476	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—IL6—ovarian cancer	1.99e-05	0.000474	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—FASN—ovarian cancer	1.99e-05	0.000474	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—AKT1—ovarian cancer	1.96e-05	0.000468	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—SLC5A5—ovarian cancer	1.96e-05	0.000466	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—SMARCA4—ovarian cancer	1.95e-05	0.000464	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—PGR—ovarian cancer	1.94e-05	0.000462	CbGpPWpGaD
Fluticasone Propionate—PGR—Generic Transcription Pathway—MYC—ovarian cancer	1.94e-05	0.000461	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—EREG—ovarian cancer	1.9e-05	0.000453	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—SLC2A1—ovarian cancer	1.89e-05	0.00045	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—IL2—ovarian cancer	1.87e-05	0.000445	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.85e-05	0.000441	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—BRIP1—ovarian cancer	1.83e-05	0.000437	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PPP1CC—ovarian cancer	1.83e-05	0.000437	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—CYP1B1—ovarian cancer	1.81e-05	0.000432	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—PARP1—ovarian cancer	1.8e-05	0.000429	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—ESR1—ovarian cancer	1.79e-05	0.000427	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PGR—ovarian cancer	1.78e-05	0.000424	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—YAP1—ovarian cancer	1.7e-05	0.000405	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PARP1—ovarian cancer	1.66e-05	0.000395	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PPP2R1A—ovarian cancer	1.65e-05	0.000392	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PPP2R1A—ovarian cancer	1.61e-05	0.000383	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	1.6e-05	0.000381	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—VEGFA—ovarian cancer	1.59e-05	0.000378	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—IL6ST—ovarian cancer	1.59e-05	0.000377	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—MAPK3—ovarian cancer	1.57e-05	0.000375	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—NRAS—ovarian cancer	1.57e-05	0.000373	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—MYC—ovarian cancer	1.53e-05	0.000364	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PIK3CG—ovarian cancer	1.52e-05	0.000363	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—NME2—ovarian cancer	1.51e-05	0.00036	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—MAPK3—ovarian cancer	1.5e-05	0.000357	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—ABCB1—ovarian cancer	1.49e-05	0.000355	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—TYMS—ovarian cancer	1.47e-05	0.000349	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—PPP2R1A—ovarian cancer	1.46e-05	0.000348	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—MAPK1—ovarian cancer	1.43e-05	0.00034	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—FASN—ovarian cancer	1.39e-05	0.00033	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—SLC5A5—ovarian cancer	1.36e-05	0.000325	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—KRAS—ovarian cancer	1.35e-05	0.000321	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PPP2R1A—ovarian cancer	1.34e-05	0.00032	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PIK3CD—ovarian cancer	1.34e-05	0.000319	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—SLC2A1—ovarian cancer	1.32e-05	0.000314	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TERT—ovarian cancer	1.31e-05	0.000311	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—CYP1B1—ovarian cancer	1.26e-05	0.000301	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—PIK3CA—ovarian cancer	1.24e-05	0.000295	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—YAP1—ovarian cancer	1.23e-05	0.000293	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CAV1—ovarian cancer	1.21e-05	0.000288	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—TP53—ovarian cancer	1.2e-05	0.000286	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—CAV1—ovarian cancer	1.18e-05	0.000281	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PIK3CB—ovarian cancer	1.17e-05	0.000278	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—ESR1—ovarian cancer	1.17e-05	0.000277	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—HRAS—ovarian cancer	1.15e-05	0.000273	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IL6ST—ovarian cancer	1.15e-05	0.000273	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.13e-05	0.000269	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—CXCL8—ovarian cancer	1.12e-05	0.000267	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PPP2R1A—ovarian cancer	1.12e-05	0.000267	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—MYC—ovarian cancer	1.12e-05	0.000266	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—APC—ovarian cancer	1.1e-05	0.000262	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PIK3CG—ovarian cancer	1.1e-05	0.000262	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PIK3CG—ovarian cancer	1.08e-05	0.000256	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—IL2—ovarian cancer	1.07e-05	0.000255	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TERT—ovarian cancer	1.07e-05	0.000254	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—AKT1—ovarian cancer	1.06e-05	0.000253	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—ABCB1—ovarian cancer	1.04e-05	0.000248	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—ESR1—ovarian cancer	1.04e-05	0.000247	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—TYMS—ovarian cancer	1.02e-05	0.000243	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—AKT1—ovarian cancer	1.01e-05	0.000241	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—FASN—ovarian cancer	1e-05	0.000239	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CAV1—ovarian cancer	9.88e-06	0.000235	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—SLC5A5—ovarian cancer	9.86e-06	0.000235	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—CYTB—ovarian cancer	9.75e-06	0.000232	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PIK3CD—ovarian cancer	9.68e-06	0.000231	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—MAPK3—ovarian cancer	9.58e-06	0.000228	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—SLC2A1—ovarian cancer	9.52e-06	0.000227	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—ESR1—ovarian cancer	9.52e-06	0.000227	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PIK3CD—ovarian cancer	9.46e-06	0.000225	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IL6ST—ovarian cancer	9.36e-06	0.000223	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—MYC—ovarian cancer	9.32e-06	0.000222	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—CYP1B1—ovarian cancer	9.13e-06	0.000217	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—APC—ovarian cancer	9e-06	0.000214	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PIK3CG—ovarian cancer	9e-06	0.000214	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—NRAS—ovarian cancer	9e-06	0.000214	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—MAPK3—ovarian cancer	8.62e-06	0.000205	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—ERBB2—ovarian cancer	8.55e-06	0.000204	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PPP1CC—ovarian cancer	8.52e-06	0.000203	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—BRIP1—ovarian cancer	8.52e-06	0.000203	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PIK3CB—ovarian cancer	8.44e-06	0.000201	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MTOR—ovarian cancer	8.44e-06	0.000201	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PIK3CB—ovarian cancer	8.25e-06	0.000196	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—CAV1—ovarian cancer	8.23e-06	0.000196	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—MAPK1—ovarian cancer	8.2e-06	0.000195	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—EGFR—ovarian cancer	8.2e-06	0.000195	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CXCL8—ovarian cancer	8.11e-06	0.000193	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	8.1e-06	0.000193	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CDKN1B—ovarian cancer	7.92e-06	0.000189	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PIK3CD—ovarian cancer	7.91e-06	0.000188	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CASP3—ovarian cancer	7.76e-06	0.000185	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IL2—ovarian cancer	7.75e-06	0.000185	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—KRAS—ovarian cancer	7.74e-06	0.000184	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CCND1—ovarian cancer	7.56e-06	0.00018	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—ABCB1—ovarian cancer	7.52e-06	0.000179	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PIK3CG—ovarian cancer	7.5e-06	0.000179	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CTNNB1—ovarian cancer	7.48e-06	0.000178	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—TYMS—ovarian cancer	7.38e-06	0.000176	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MMP9—ovarian cancer	7.34e-06	0.000175	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PTEN—ovarian cancer	7.29e-06	0.000174	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PTEN—ovarian cancer	7.12e-06	0.00017	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PIK3CA—ovarian cancer	7.11e-06	0.000169	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—ERBB2—ovarian cancer	6.99e-06	0.000166	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MTOR—ovarian cancer	6.89e-06	0.000164	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PIK3CB—ovarian cancer	6.89e-06	0.000164	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CXCL8—ovarian cancer	6.63e-06	0.000158	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PIK3CD—ovarian cancer	6.59e-06	0.000157	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—VEGFA—ovarian cancer	6.59e-06	0.000157	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—HRAS—ovarian cancer	6.58e-06	0.000157	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—STAT3—ovarian cancer	6.52e-06	0.000155	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—NRAS—ovarian cancer	6.51e-06	0.000155	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CDKN1B—ovarian cancer	6.47e-06	0.000154	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—AKT1—ovarian cancer	6.46e-06	0.000154	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CASP3—ovarian cancer	6.34e-06	0.000151	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IL2—ovarian cancer	6.33e-06	0.000151	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—IL6—ovarian cancer	6.3e-06	0.00015	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MAPK3—ovarian cancer	6.23e-06	0.000148	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CCND1—ovarian cancer	6.17e-06	0.000147	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CTNNB1—ovarian cancer	6.11e-06	0.000146	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MYC—ovarian cancer	6.06e-06	0.000144	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MMP9—ovarian cancer	5.99e-06	0.000143	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PTEN—ovarian cancer	5.96e-06	0.000142	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—CAV1—ovarian cancer	5.95e-06	0.000142	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MAPK1—ovarian cancer	5.93e-06	0.000141	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—EGFR—ovarian cancer	5.93e-06	0.000141	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—AKT1—ovarian cancer	5.81e-06	0.000138	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PIK3CB—ovarian cancer	5.75e-06	0.000137	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—YAP1—ovarian cancer	5.72e-06	0.000136	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—KRAS—ovarian cancer	5.6e-06	0.000133	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—MAPK3—ovarian cancer	5.54e-06	0.000132	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PIK3CG—ovarian cancer	5.42e-06	0.000129	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—MYC—ovarian cancer	5.39e-06	0.000128	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—VEGFA—ovarian cancer	5.38e-06	0.000128	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—STAT3—ovarian cancer	5.33e-06	0.000127	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—NRAS—ovarian cancer	5.31e-06	0.000127	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PIK3CA—ovarian cancer	5.14e-06	0.000122	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MAPK3—ovarian cancer	5.09e-06	0.000121	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PIK3CA—ovarian cancer	5.03e-06	0.00012	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TP53—ovarian cancer	4.98e-06	0.000118	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PTEN—ovarian cancer	4.96e-06	0.000118	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MYC—ovarian cancer	4.95e-06	0.000118	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MAPK1—ovarian cancer	4.84e-06	0.000115	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—EGFR—ovarian cancer	4.84e-06	0.000115	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PIK3CD—ovarian cancer	4.77e-06	0.000113	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—HRAS—ovarian cancer	4.76e-06	0.000113	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—FASN—ovarian cancer	4.66e-06	0.000111	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—SLC5A5—ovarian cancer	4.58e-06	0.000109	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—KRAS—ovarian cancer	4.57e-06	0.000109	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IL6—ovarian cancer	4.56e-06	0.000108	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.43e-06	0.000105	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.25e-06	0.000101	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PIK3CA—ovarian cancer	4.2e-06	0.0001	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—AKT1—ovarian cancer	4.2e-06	0.0001	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PIK3CB—ovarian cancer	4.15e-06	9.89e-05	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—AKT1—ovarian cancer	4.11e-06	9.78e-05	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TP53—ovarian cancer	4.07e-06	9.68e-05	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—HRAS—ovarian cancer	3.89e-06	9.26e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.76e-06	8.96e-05	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—AKT1—ovarian cancer	3.74e-06	8.89e-05	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IL6—ovarian cancer	3.72e-06	8.86e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PTEN—ovarian cancer	3.59e-06	8.54e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PIK3CA—ovarian cancer	3.5e-06	8.34e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.5e-06	8.32e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—TYMS—ovarian cancer	3.43e-06	8.17e-05	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—AKT1—ovarian cancer	3.43e-06	8.17e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—AKT1—ovarian cancer	2.86e-06	6.81e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—CAV1—ovarian cancer	2.77e-06	6.59e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.53e-06	6.03e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.52e-06	6e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.22e-06	5.27e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—AKT1—ovarian cancer	2.07e-06	4.92e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.93e-06	4.6e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PTEN—ovarian cancer	1.67e-06	3.97e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.18e-06	2.8e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—AKT1—ovarian cancer	9.62e-07	2.29e-05	CbGpPWpGaD
